by admin | Jun 1, 2021
Omalizumab (Xolair®) is a recombinant humanized monoclonal anti-IgE antibody, which binds to free IgE, lowers free IgE levels, and causes FcεRI receptors on basophils and mast cells to be downregu-lated. Omalizumab is the first drug approved as an add-on therapy for...
by admin | May 31, 2021
Background Chronic urticaria (CU) is a common disease, characterized by the recurrent appearance of wheals, angioedema or both for more than 6 weeks. Its underlying biology is not well understood, and many patients do not obtain sufficient relief from recommended...
by admin | May 31, 2021
Introduction: The COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: To understand how CU patients are affected by the COVID-19 pandemic; how...
by admin | May 31, 2021
Purpose: Patients with chronic spontaneous urticaria (CSU) have an increased risk for comorbid autoimmune diseases. In this retrospective multicenter study of CSU patients, we evaluated clinical and laboratory features of CSU associated with a higher risk of comorbid...
by admin | Mar 17, 2021
Background: Chronic urticaria (CU) is a common skin disorder, which can be further divided into chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Omalizumab is effective and safe for difficult-to-treat CSU based on clinical trials. However,...
Recent Comments